However, our data describe the novel finding that signal pathway reprogramming is a potential resistance mechanism for CLL cells and cytotoxic therapies, a finding that is particularly exciting for our understanding of the role BCR engagement plays in the pathophysiology of this disease. Here, BCR is linked to B-cell chronic lymphocytic leukemia.